Autoimmune

CAR-T Cell Therapy Achieves 87.5% Remission Rate in Autoimmune Disease

Groundbreaking phase 1/2 CASTLE trial shows CD19 CAR-T cell therapy achieves complete drug-free remission in 87.5% of patients with refractory lupus, scleroderma and myopathies who failed all previous treatments.